Live Breaking News & Updates on Alexion Pharmaceuticals Inc|Page 5

Stay updated with breaking news from Alexion pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Avalo Therapuetics (AVTX) Appoints Biotech Leaders to its Board

Avalo Therapuetics (AVTX) Appoints Biotech Leaders to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San Francisco , United States , City Of , United Kingdom , Columbia University , New York , University Of California At Berkeley , University Of California San Francisco , Artios Pharma , Jonathan Goldman , Garrya Neil , Samantha Truex , Aaron Kantoff , George Hospital Medical School , Point Biomedical Corp , San Francisco Veterans Administration Medical Center , Corporate Development At Genzyme , Thayer School Of Engineering At Dartmouth , Centessa Pharmaceuticals , Dartmouth College , Corporate Development At Biogen Inc , Alexion Pharmaceuticals Inc , Tuck School At Dartmouth , Novo Nordisk , Thayer School At Dartmouth , Bartholomew Hospital Medical College ,

AstraZeneca : Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH - Form 6-K -April 02, 2024 at 08:48 am EDT

A9026i

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or. ....

University Of Washington Medical Center , United States , United Kingdom , Glasgow City , Marc Dunoyer , Adrian Kemp , Bart Scott , Division Of Hematology , European Hematology Association , Securities Exchange , Company Secretary , European Medicines Agency , Investor Relations Team , Commission File Number , Alexion Pharmaceuticals Inc , European Union , Drug Administration , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Lancet Haematology , Washington Medical Center , Clinical Research Division , Fred Hutchinson Cancer Center ,

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , Glasgow City , Voydeyaplus Solirisor , Bart Scott , Marc Dunoyer , European Hematology Association , European Union , University Of Washington Medical Center , European Medicines Agency , Alexion Pharmaceuticals Inc , Drug Administration , Division Of Hematology , Lancet Haematology , Washington Medical Center , Clinical Research Division , Fred Hutchinson Cancer Center , Chief Executive Officer , Functional Assessment , Chronic Illness Therapy , Breakthrough Therapy , European Medicines , Orphan Drug Designation , Patient Safety Card , Mitigation Strategy , Prescribing Information ,

AstraZeneca Ultomiris granted approval in US for treatment of adults with neuromyelitis optica spectrum disorder

Ultomiris, the first long-acting C5 complement inhibitor, shows promise in reducing relapse risk for AQP4 Ab+ NMOSD patients. Learn more here. ....

United Kingdom , New Zealand , United States , Neuromyelitis Optica , Histochem Cytochem , European Union , Drug Administration , Alexion Pharmaceuticals Inc , North America , Expanded Disability Status Scale Score , Astrazeneca Rare Disease , Alexion Pharmaceuticals , Rare Diseases , Ann Neurol , Curr Treat Options , South East , Nat Rev , Prog Histochem , Neuromyelitis Optica Spectrum Disorder Using , Safety Study , Adult Participants With ,

AstraZeneca : Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) - Form 6-K -March 25, 2024 at 07:31 am EDT

A0626i

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or. ....

United States , United Kingdom , New Zealand , Marc Dunoyer , Seanj Pittock , Adrian Kemp , Neuromyelitis Optica , Histochem Cytochem , Drug Administration , Mayo Neuroimmunology Laboratory , Mayo Clinic Center , Securities Exchange , European Union , Investor Relations Team , Alexion Pharmaceuticals Inc , Commission File Number , Company Secretary , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Mayo Clinic , Multiple Sclerosis , Autoimmune Neurology , Neuroimmunology Laboratory ,